Thursday, April 8th, 2010 - Bionomics Limited
Bionomics has achieved significant clinical milestones and broadened the commercial opportunities for each of its lead assets – anti cancer compound BNC105 and BNC210 which is being developed for the treatment of anxiety.

When the clinical trial of BNC210 was initiated we were able to say that in less than 2 years the Bionomics’ team of scientists and drug developers had been able to progress two newly discovered drugs into clinical trials – illustrating not only the capacity of our powerful drug discovery engine to generate high value drug candidates, but also the disciplined approach we employ to effectively execute the transition of new drugs into the clinic.

In addition to meeting important clinical milestones, Bionomics’ scientists have continued to conduct research which seeks to expand the commercial opportunity for both BNC105 and BNC210. They have also presented the results of their work at major US conferences.

Overall revenue was $4.29 million and with our major $15 million capital raising now completed, Bionomics is in a very strong position to execute our clinical development plans for BNC105 and BNC210. We were very pleased with the support of our major shareholders and also that of our smaller shareholders who participated through the Share Purchase Plan in this capital raising which has placed Bionomics in a financial position much envied by other Australian biotech companies.

Bionomics is confident of reaching a number of important value-add milestones over the next 12 months.

BNC105
- Initiation of Phase II renal cancer trial Q4/Q1, 2009/2010
- Contract to enter into second Phase II cancer clinical trial Q4, 2009
- Initiation of second Phase II clinical trial Q1, 2010
- Presentation of BNC105 clinical data at ASCO Q2, 2010
- Presentation of BNC105 data at AACR Q2, 2010
- Interim Phase II clinical data Q4, 2010

BN C210
- Complete Stage 2 of current Phase I clinical trial Q4, 2009
- Initiate second Phase I clinical trial Q1, 2010
- Complete second Phase I clinical trial Q2, 2010

Contact Profile

Bionomics Limited


Bionomics (ASX: BNO) discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. Bionomics' most advanced program, BNC105 for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, the company's angiogenesis target and drug discovery platform, incorporates a variety of genomics tools to identify and validate novel angiogenesis targets. MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system.
Dr Deborah Rathjen
P: +61883546101
M: +61418160425
W: www.bionomics.com.au

Keywords

Bionomics has achieved significant clinical milestones and broadened the commercial opportunities for each of its lead assets – anti cancer compound BNC105 and BNC210 which is being developed for the treatment of anxiety.

Categories

Sharing

More Formats